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Leptin plays a central role in weight control by suppressing food intake and increasing energy expenditure.
The concept of leptin resistance emerged to explain the seemingly paradoxical elevated leptin levels in
obesity. Recent discoveries reveal that protein tyrosine phosphatases are key players in leptin resistance
by globally suppressing leptin signaling.Introduction
A central aspect of systemic physiology is energy balance. Indi-
viduals are said to be in a state of energy balance when energy
intake, in the form of food and drinks, equals energy expenditure,
in the forms of physical activity and basal metabolism, which
represents the sum of all biochemical reactions occurring in
our body at rest. The ability of healthy individuals to maintain
body weight in the face of fluctuating energy intake and expen-
diture is due to an intricate physiological network that acts as
the gatekeeper of energy balance. Indeed, under normal physio-
logical conditions, any deviation in energy intake or expenditure
is compensated for by physiological and behavioral responses
that oppose these changes in order to return to a state of energy
balance. However, this physiological state of energy balance is
perturbed in several pathological conditions (Figure 1). Negative
energy balance is associated with weight loss and diseases such
as anorexia and cachexia. A more prevalent state of energy
imbalance is positive energy balance, which is associated with
weight gain, obesity, and metabolic syndrome. Indeed, obesity
in now considered a very significant health threat because nearly
30% of the adult population in Europe and America is clinically
obese (WHO Statistics 2011).
In recent years there has been significant progress in under-
standing the complex physiological network that regulates
energy balance. Two central discoveries in the elucidation of
this network were those of leptin, which is encoded by the ob
gene, and its receptor, LepRb (also known as ObRb) (Wauman
and Tavernier, 2011). The word leptin originates from the Greek
root leptos, which means ‘‘thin’’; upon its identification, leptin
was seen as a cytokine produced by adipocytes whose main
function was to counteract obesity. Leptin role is now appreci-
ated to be far more complex, notably as a global messenger to
the central nervous system (CNS) of systemic energy stores
(Myers et al., 2010). Increased leptin levels signal to the CNS
that energy stores are sufficient, whereas decreased leptin levels
signal that energy levels are dropping, resulting in increased
appetite and metabolic efficiency. Leptin acts on specific popu-
lations of neurons in the brain, including hypothalamic, midbrain,
and brainstem neurons. This leads to stimulation of energy
expenditure and inhibition food intake. A well-characterized
neuronal circuit for leptin action involves increased expression292 Cell Metabolism 15, March 7, 2012 ª2012 Elsevier Inc.of the anorexigenic peptide alpha-melanocyte stimulating
hormone (alpha-MSH), derived from pro-opiomelanocortin
(POMC), and decreased expression of orexigenic peptides
neuropeptide Y (NPY) and agouti-related peptide (AgRP; (Wau-
man and Tavernier, 2011). This way, leptin can impact both the
intake and expenditure sides of the energy balance equation.
Leptin deficiency results in obesity in rodents and humans,
owing to hyperphagia and inappropriate metabolism elicited by
the CNS, which perceives low energy levels in the presence of
sufficient energy stores. In diet-induced obesity, leptin levels
are elevated, reflecting increased fat stores. Importantly, injec-
tion of additional leptin in obese individuals fails to counteract
obesity (Myers et al., 2010). These observations highlight that
obese individuals are less responsive to the action of leptin.
This led to the concept of leptin resistance. The extent to which
leptin resistance is associated with the etiology of obesity or is
a consequence of obesity is still unclear. Several mechanisms
have been put forward to explain leptin resistance, notably
impaired transport of leptin across the blood brain barrier,
endoplasmic reticulum (ER) stress, and inflammation, as well
as attenuation of leptin signaling by SOCS3 and protein tyrosine
phosphatases (PTPs); (Myers et al., 2010; Wauman and Taver-
nier, 2011) (Figure 1). Clearly, multiple biological processes can
promote obesity/leptin resistance and interfere with leptin func-
tions. In this review, we focus on the recent developments in the
field of PTPs that highlight their importance in attenuating leptin
action through downstream signaling modulations (SHP2 and
PTEN) or close interactions with leptin receptor-associated
proteins (i.e., PTP1B, TC-PTP, and RPTP epsilon).
Leptin Signaling
LepRb is a member of the class 1 cytokine receptor family. It is
expressed in the brain and possesses a long, multidomain extra-
cellular region, a transmembrane region, and an elongated intra-
cellular domain that couples to downstream signaling cascades.
LepRb signaling is elicited by its associated Jak2 tyrosine kinase
because it does not have intrinsic kinase activity (Figure 2). Upon
leptin binding, LepRb undergoes a conformational change,
leading to phosphorylation and activation of Jak2. Once acti-
vated, Jak2 phosphorylates three tyrosine residues in the cyto-
plasmic domain of the receptor (Y985, Y1077, and Y1138 in
Figure 1. Normal and Leptin Resistance Physiology
In normal conditions, leptin acts on specific populations of neurons to increase the expression of anorexigenic peptides and reduce the expression of the
orexigenic peptides. This effect produces reduced appetite and increased energy expenditure, which both contribute to themaintenance ofmetabolic balance. In
contrast, the impact of leptin on energy homeostasis is diminished in some pathological conditions where specific molecular events impair leptin’s actions
(illustrated with the dotted lines). These physiological events translate into increased adipocyte mass and a positive trigger for even more leptin secretion by the
fat tissues.
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engage with downstream signaling pathways by recruiting
proteins containing SH2 phosphotyrosine recognition domains.
The most studied pathway coupled to leptin signaling is the
Jak/Stat pathway. pY1138 recruits the transcription factor
STAT3, which becomes phosphorylated by Jak2. pSTAT3
then homodimerizes and translocates to the nucleus, where it
increases the expression of POMC and inhibits that of NPY.
pSTAT3 also increases the expression of SOCS3, which acts
as a feedback inhibitor of leptin signaling by binding to
pY985 and preventing the activation of Jak2. In addition to
STAT3, leptin activation of its receptor also leads to the phos-
phorylation and activation of STAT5. STAT5 binds pY1138
and pY1077 on the LepRb. However, specific transcriptional
effects of STAT5 homodimers on leptin signaling have not
yet been identified. The importance of STAT3 and STAT5 in
mediating the effects of leptin is well illustrated by the fact
that their individual deletion in the CNS is accompanied by
hyperphagia and obesity (Myers et al., 2010; Wauman and
Tavernier, 2011).
Leptin signaling also engages the ERK pathway. pY985
recruits the protein tyrosine phosphatase SHP2, which ultimately
leads to the phosphorylation and activation of ERK kinase. The
involvement of the ERK pathway is supported by the fact that
inhibition of ERK blocked the effect of leptin on food intake
and body weight (Wauman and Tavernier, 2011).
Another important pathway in relaying leptin signaling is PI3K.
Insulin receptor substrate (IRS) 1 or 2 is recruited to LepRb via
SH2B1, resulting in their phosphorylation by JAK2. IRS then acti-
vates PI3K, leading to the production of phosphatidylinositol3,4,5 triphosphate (PIP3). PIP3 formation results in Akt activation,
which then prevents FoxO1 from inhibiting the expression of
POMC and stimulating the expression of NPY and AgRP. Over-
all, PI3K promotes leptin actions by inhibiting FoxO1. Indeed, it
has been shown that FoxO1 antagonizes leptin action in vivo
(Wauman and Tavernier, 2011).
In addition to these pathways, it is worth mentioning that the
mTOR and AMPK pathways are also key effectors of leptin
signaling. Interestingly, there is significant crosstalk between
these pathways. Therefore, the biological consequences of lep-
tin signaling will be dependent on the balance between the
different downstream effector branches.
PTPs in Leptin Signaling
The main molecular mechanism behind leptin signaling is tyro-
sine phosphorylation of key signaling components by protein
tyrosine kinases (PTKs). By opposing the activity of PTKs, PTPs
have emerged as central players that regulate leptin signaling.
PTPs consist of a large family, containing 107 members and
divided into four classes based on the amino acid sequence of
their catalytic domain (Julien et al., 2011). Members of classes
1, 2, and 3 display the consensus catalytic domain signature
(H/V)C(X)5R(S/T), where the cysteine and arginine residues are
invariant and essential for catalysis. Members of class 4 rely on
a different mechanism for enzyme function that is dependent
on the presence of an aspartic acid residue. Class 1 contains
the vast majority of the PTP members and is divided into two
subfamilies, the classical and dual-specificity phosphatases
(Dsps). The Dsps display serine, threonine, and tyrosine phos-
phatase activities.Cell Metabolism 15, March 7, 2012 ª2012 Elsevier Inc. 293
Figure 2. Protein Tyrosine Phosphatases Involved in Leptin Signaling
Upon activation of LepRb, the receptor induces activation of the Jak2 tyrosine kinase, which, in turn, phosphorylates tyrosine 985, 1077, and 1138 on LepRb.
These phosphorylated tyrosines becomedocking sites for subordinate signaling proteins, such as SHP2, SOCS3, and STATS 3 and 5, leading to the physiological
action of leptin. Specific protein tyrosine phosphatases can modulate this cascade in a negative (closed red ovals) or a positive (open red oval) way. The
physiological consequences of tyrosine dephosphorylation led by PTP1B andRPTPe on Jak2, TC-PTP on STAT3, and PTEN on PIP3 generated by PI3K activities,
are to attenuate leptin signaling. In contrast, the recruitment of SHP2 to pTyr 985, which is also a binding site for the negative modulator SOCS3, positively
engages the ERK pathway. Attenuation of LepRb signaling decreases pSTAT3 and STAT5 homodimerization and translocation to the nucleus. For the population
of STATs homodimers that succeed in entering the nucleus, a portion of those would be subjected to TC-PTP dephosphorylation. In the end, the attenuation of
leptin signaling by PTPs can lead to leptin resistance.
Cell Metabolism
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signaling: SHP2, PTEN, PTP1B, and the recently implicated
TCPTP and RPTP epsilon (Figure 2). With the exception of
SHP2 that globally promotes leptin signaling by coupling to
ERK kinase, all of the other four phosphatases work by inhibiting
leptin signaling.
SHP2
SHP2 is a class 1 classical nonreceptor PTP, also called
PTPN11, located in the cytoplasm. In vitro experiments sug-
gested that SHP2 may function both as a positive and negative
regulator of leptin signaling (Feng, 2006). Indeed, SHP2 has
been shown to promote signaling through the ERK pathway,
whereas other data indicated that it may suppress JAK2/294 Cell Metabolism 15, March 7, 2012 ª2012 Elsevier Inc.STAT3 signaling by decreasing JAK2 phosphorylation (Feng,
2006). The overall physiological relevance of SHP2 in leptin
signaling was revealed by the engineering of SHP2-null mouse
models. In CaMKIIalpha-cre mice, deletion of SHP2 in postmi-
totic forebrain neurons resulted in a knockout (KO) mouse
model, named CaSKO, that developed both obesity and leptin
resistance (Zhang et al., 2004), revealing that the global effect
of SHP2 in these neurons promotes leptin signaling. Indeed,
CaSKO mice revealed that SHP2-mediated promotion of ERK
signaling in the brain overrode SHP2-mediated inhibition of
JAK2/STAT3 signaling (Zhang et al., 2004). A global neuronal
deletion of SHP2 also resulted in obesity and leptin resistance
(Krajewska et al., 2008), and POMC neuron-specific deletion of
SHP2 resulted in elevated adiposity and decreased leptin
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support a role for SHP2 as a positive regulator of leptin signaling
in the brain.
The phenotype of mice with neuronal deletion of SHP2, which
signals at Y985 of the LepRb, contrasts with the general pheno-
type ofmice lacking signaling fromY985.While neuronal deletion
of SHP2 is associated with obesity and leptin resistance, female
mice harboring homozygous Y985 to leucine mutation display
elevated leptin sensitivity and protection from diet-induced
obesity (Bjo¨rnholm et al., 2007). To understand these contrasting
phenotypes, it is important to appreciate that both SOCS3 and
SHP2 bind to pY985. It is possible that SHP2 neuronal loss
permits unrestricted binding of SOCS3 to pY985, leading to
greater inhibition of leptin signaling. In mice harboring homozy-
gous mutation at Y985, SOCS3 would not be able to bind to
Y985, thereby limiting feedback inhibition of leptin signaling.
Finally, the impact of SHP2 loss on leptin sensitivity and body
weight could also bemediated by additional signaling pathways.
Indeed, SHP2 contributes to many signaling pathways down-
stream of various receptors in addition to LepRb (Feng, 2006).
PTEN
Phosphatase and tensin homolog deleted on chromosome 10
(PTEN) is a class 1 Dsp known mainly for its tumor suppressor
functions (Julien et al., 2011). PTEN does not impact proximal
LepRb signaling in the same manner as the other four phospha-
tases discussed in this review. Indeed, PTEN plays an important
role in leptin signaling, due to its role as a negative regulator of
the PI3K pathway. Biochemical experiments using hypothalamic
cells demonstrated that leptin leads to the phosphorylation of
PTEN in a casein kinase II (CK2)- and glycogen synthase kinase
3 (GSK3)-dependent manner, resulting in the inhibition of its
phosphatase activity (Ning et al., 2009). By inhibiting the phos-
phatase activity of PTEN, leptin ensures the relay of its signal
to the PI3K pathway. In support of this, mice with deletion of
PTEN in leptin-sensitive neurons displayed increased PI3K
signaling and were leaner than controls (Plum et al., 2007). On
the contrary, mice harboring POMC neuron-specific deletion of
PTEN displayed leptin resistance and obesity associated with
elevated KATP channel activity, causing diminished firing rate
(Plum et al., 2006). Also, ablation of PTEN in steroidogenic factor
1 (SF-1)-expressing neurons of the ventromedial hypothalamus
(VMH) in mice resulted in elevated body weight and increased
food intake on normal diet (Klo¨ckener et al., 2011). Together,
these results suggest that other populations of neurons compen-
sate for the impact of PTEN deletion in POMC and SF-1 neurons
in mice with PTEN deletion in all leptin-sensitive neurons. These
studies highlight the importance of examining the role of leptin-
signaling components in various neuronal populations. In this re-
gard, leptin has been shown to promote or inhibit PI3K signaling
depending on the type of hypothalamic neurons (Xu et al., 2005).
PTP1B
PTP1B is a class 1 nonreceptor PTP. It is attached to the cyto-
plasmic face of the endoplasmic reticulum. The first indication
of a role for PTP1B in attenuating leptin signaling came with
the generation of PTP1B null mice. These mice were lean and
resistant to diet-induced obesity (Elchebly et al., 1999). It was
later shown that PTP1B can interact with and dephosphorylateJak2, and that PTP1B null mice display enhanced phosphoryla-
tion of STAT 3 in response to leptin. These molecular changes
were accompanied by significant weight loss and feeding inhibi-
tion (Cheng et al., 2002; Zabolotny et al., 2002). Together, these
data indicate that PTP1B inhibits leptin signaling by dephosphor-
ylating Jak2. The impact of PTP1B on leptin signaling in the brain
is clearly central to the leptin hypersensitivity and resistance to
diet-induced obesity of PTP1B null mice because neuronal-
and POMC-specific deletions of PTP1B also lead to enhanced
leptin sensitivity and resistance to diet-induced obesity (Banno
et al., 2010; Bence et al., 2006). Interestingly, mice with neuronal
deletion of PTP1B display increased energy expenditure and
reduced food intake, whereas mice with POMC neuronal dele-
tion of PTP1B only display increased energy expenditure (Banno
et al., 2010; Bence et al., 2006). These data suggest that PTP1B
in POMC neurons regulates energy expenditure but not food
intake, and that other neuronal populations are responsible for
the impact of PTP1B on food intake.
It has been suggested that PTP1B may play a role in the
etiology of leptin resistance because high-fat diet is accompa-
nied by elevated PTP1B expression (White et al., 2009). In addi-
tion to regulating the expression of PTP1B, diet-induced obesity
may impact the intrinsic activity of PTP1B. The activity of PTP1B
can be regulated by oxidation, phosphorylation, sumoylation,
and proteolysis. However, it remains to be elucidated how these
regulatory mechanisms could modulate the impact of PTP1B on
leptin signaling. This is particularly relevant given that much
effort is underway to therapeutically inhibit PTP1B in the context
of obesity and diabetes.
TC-PTP
TC-PTP is a nonreceptor, classical PTP in the N1 subtype, which
shares 72% identity and structural similarity with PTP1B. The
TC-PTP-deficient mouse model presents a severe and broad
inflammatory profile, leading to lethality at 3–4 weeks of age
(You-Ten et al., 1997). Central to this phenotype is the release
of several inflammatory cytokines, indicating that TC-PTP acts
as an important negative regulator of cytokine signaling. Indeed
the target specificities of PTP1B and TC-PTP are complemen-
tary with TC-PTP dephosphorylating Jak1 and Jak3 and
PTP1B targeting Jak2 and Tyk2 (Myers et al., 2001; Simoncic
et al., 2002). Moreover, TC-PTP has been reported to recognize
and remove phosphatemoiety from specific tyrosines on various
members of the STAT transcription factors family downstream of
Jak kinases activation, including STAT1 and STAT3 (ten Hoeve
et al., 2002). Importantly, STAT3 serves as a transducer of
Jak2 downstream of the leptin receptor. Recently, Loh and
collaborators (2011) reported a role for TC-PTP in leptin
signaling. Interestingly, they demonstrated that in the hypothal-
ami of high fat-fed wild-type animals, TC-PTP mRNA and its
protein levels increased 1.4- and 2-fold respectively. The authors
also found a similar increase in TC-PTP when animals were
systemically injected with leptin. These first experiments
suggested that at least part of a compensative response to lep-
tin signaling levels could be conveyed through increased expres-
sion of TC-PTP in the hypothalamus. These findings also
correlated to the phenotype of nestin-cre depletion of TC-PTP
in the hypothalamus of TC-PTP flox mice. Ablation of TC-PTP
in the hypothalamus led to increased signaling downstream ofCell Metabolism 15, March 7, 2012 ª2012 Elsevier Inc. 295
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as well as increased sensitivity to leptin at a systemic level and
the development of obesity resistance following high-fat diet
(Loh et al., 2011).
Hence, it is interesting that two closely related PTPs act at
sequential levels (PTP1B on Jak2 and TC-PTP in STAT3) down-
stream of the leptin receptor. To examine further the potential
synergy between PTP1B and TC-PTP in modulating the action
of leptin, Loh and collaborators (2011) expanded on these find-
ings by breeding together the floxed TC-PTP and floxed
PTP1B mice (Bence et al., 2006) with nestin-cre animals. Not
only were the double-KO animals more resistant to diet induced
obesity, they also showed a significant increase in leptin sensi-
tivity compared to the PTP1B nestin cre KO animals. These
elegant studies revealed the additive regulation that occurs
when both of these closely related enzymes are targeted.
RPTP Epsilon
Among the entire subfamily of tyrosine specific PTPs, 21 are
receptor PTPs that localize to the plasma membrane and recog-
nize both membrane-associated and cytoplasmic tyrosine-
phosphorylated proteins. RPTP epsilon (RPTPe) is one of the
best known members of this subfamily. Although mice with
a full deletion of this enzyme do not demonstrate any severe
systemic phenotypes (Tiran et al., 2006), detailed analyses iden-
tified this receptor PTP as a key regulator of several biological
functions. For example, RPTP acts as an activator of src-like
kinases in cancer and also plays a central role in osteoclast func-
tion and hematopoietic cell-lineage differentiation. Because
RPTPe null animals presented with lower weight than their
wild-type counterparts, Rousso-Noori and collaborators (2011)
examined the potential role of RPTPe in systemic metabolism.
When challenged with high-fat diet, the RPTPe-KO mice were
resistant to weight gain, which was particularly significant after
ovariectomy. RPTPe-deficient mice showed a decrease in circu-
lating leptin levels and an associated leptin hypersensitivity, as
detected by high STAT3 phosphorylation in the hypothalamus.
Upon examination of upregulated leptin signaling in RPTPe null
mice, Rousso-Nori and collaborators found an interesting nega-
tive feedback loop, whereby the activation of leptin receptor
leads to the phosphorylation of tyrosine 605 on RPTPe, a phos-
phorylation known to activate this receptor PTP. The conse-
quence of this activation is the direct dephosphorylation of
phospho-Jak2 by RPTPe (Rousso-Noori et al., 2011).
Future Perspective
Although five different PTPs have so far been shown tomodulate
LepRb signaling, many more have yet to be tested for their
potential in acting downstream of LepRb. Large shRNA screens
and other gene family assaysmay identify evenmore leptin regu-
lators from the PTP family. It is noteworthy that besides the
reported slight increased in TC-PTP in the PTP1B-KO hypothal-
amus, there is no known example of compensatory, increased
expression of PTP familymembers in the reported PTP-KOmice.
This suggests that although several PTPs are involved in the
negative regulation of leptin signaling, each PTP likely serves a
different function, acting at a different intracellular location and/
or with a different kinetics of activity. The pleiotropic downregu-
lation of leptin signaling by different PTPs provides a broader296 Cell Metabolism 15, March 7, 2012 ª2012 Elsevier Inc.plurality in downstream responses. Loh and collaborators
(2011) suggested that pharmacological inhibition of both
PTP1B and TC-PTP may be helpful as an anti-obesity treatment
through augmentation of leptin signaling in the brain. Although in
theory possible and desirable, the systemic inflammatory conse-
quences of inhibiting TC-PTP remain a major impediment,
notwithstanding the technical difficulties in inhibiting brain-local-
ized PTPs. This brings to light the importance of examining
heterozygous animals in PTP mouse models because the
pharmacological responses to PTP inhibition would more
likely resemble the physiology of these animals than that of com-
plete KOs.
In addition to metabolic diseases, there is renewed interest in
the importance of metabolism in supporting tumor growth. It is
now well appreciated that PTPs play a central role in regulating
both metabolism and tumor growth and, individually, they repre-
sent major pharmacological targets. Although there are still no
small-molecule inhibitors of PTPs in the clinics, notwithstanding
nucleic acid base PTP inhibition, several new directions are
currently being examined in a great number of chemistry and
PTP laboratories. This is particularly accurate for PTP1B, which
remains the overall best target in metabolic diseases.
As it stands, we know very little about the interplay between
the metabolic and growth-signaling pathways that are regulated
by PTPs. This emerging gap in knowledge will foster new
research endeavors and further justify the exciting interest in
developing novel approaches toward the inhibition of PTPases
for treating metabolic syndromes and cancers.
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